Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director | May 05, 2017 | May 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date May 05, 2017 · Filed May 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,049 |
Ending reported balance
After 2017-05-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-05-05 · Sale · Disposed 10,000 · Balance 57,049 F1: These shares were sold pursuant to a 10b5-1 trading plan. F2: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.32 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2017-05-05 · Exercise / conversion · Acquired 10,000 · Balance 67,049 F3: These shares were exercised pursuant to a 10b5-1 trading plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2017-06-20 | Direct | 0 |
Reported balance
After 2017-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-05-05 · Exercise / conversion · Disposed 10,000 · Balance 0 F3: These shares were exercised pursuant to a 10b5-1 trading plan. F7: These options were granted on June 20, 2007 and are exercisable cumulatively at a rate of 33% per annum beginning one year from date of grant. |
| Common StockSEC Table I · non-derivative | IndirectMichael D. Hooven 2004 Trust FBO Michael | 234,211 |
Reported balance
Holding disclosure · report date 2017-05-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 234,211 F4: Held by Michael D. Hooven 2004 Trust FBO Michael. Mr. Hooven disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectMichael D. Hooven 2004 Trust FBO Susan | 234,211 |
Reported balance
Holding disclosure · report date 2017-05-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 234,211 F5: Held by Michael D. Hooven 2004 Trust FBO Susan. Mr. Hooven disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSusan Spies 2004 Children's Trust | 18,421 |
Reported balance
Holding disclosure · report date 2017-05-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 18,421 F6: Held by Susan Spies 2004 Children's Trust. These shares are held in trust for the benefit of the Reporting Person's son. Reporting Person is the trustee of that trust. Mr. Hooven disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold pursuant to a 10b5-1 trading plan.
F2: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.32 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: These shares were exercised pursuant to a 10b5-1 trading plan.
F4: Held by Michael D. Hooven 2004 Trust FBO Michael. Mr. Hooven disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.
F5: Held by Michael D. Hooven 2004 Trust FBO Susan. Mr. Hooven disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.
F6: Held by Susan Spies 2004 Children's Trust. These shares are held in trust for the benefit of the Reporting Person's son. Reporting Person is the trustee of that trust. Mr. Hooven disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.
F7: These options were granted on June 20, 2007 and are exercisable cumulatively at a rate of 33% per annum beginning one year from date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2017 Filed May 9, 2017 20:51 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-17-030990 · doc4.xml · derivative · entry 6 Hooven Michael D · CIK 0001336090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F7 · derivative.exercise_date: These options were granted on June 20, 2007 and are exercisable cumulatively at a rate of 33% per annum beginning one year from date of grant. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:51 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 10,000 | $9.50 | $95,000.00 |
DisclosureSEC source: 0001209191-17-030990 · doc4.xml · nonDerivative · entry 2 Hooven Michael D · CIK 0001336090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:51 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 10,000 | $22.08 | $220,800.00 |
DisclosureSEC source: 0001209191-17-030990 · doc4.xml · nonDerivative · entry 1 Hooven Michael D · CIK 0001336090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,049 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.32 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2012 Filed Feb 23, 2017 21:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 3,500 | $10.02 | $35,070.00 |
DisclosureSEC source: 0001209191-17-013836 · doc4.xml · nonDerivative · entry 1 Hooven Michael D · CIK 0001336090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,049 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.